CN110150651A - It is a kind of for adjusting the preparation of infant's function of intestinal canal - Google Patents
It is a kind of for adjusting the preparation of infant's function of intestinal canal Download PDFInfo
- Publication number
- CN110150651A CN110150651A CN201910502600.0A CN201910502600A CN110150651A CN 110150651 A CN110150651 A CN 110150651A CN 201910502600 A CN201910502600 A CN 201910502600A CN 110150651 A CN110150651 A CN 110150651A
- Authority
- CN
- China
- Prior art keywords
- preparation
- fermentation
- infant
- function
- adjusting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 46
- 238000000855 fermentation Methods 0.000 claims abstract description 88
- 230000004151 fermentation Effects 0.000 claims abstract description 87
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 241001474374 Blennius Species 0.000 claims abstract description 58
- 241000195493 Cryptophyta Species 0.000 claims abstract description 44
- 241000894006 Bacteria Species 0.000 claims abstract description 42
- 239000004310 lactic acid Substances 0.000 claims abstract description 30
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 30
- 229920000294 Resistant starch Polymers 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 16
- 235000021254 resistant starch Nutrition 0.000 claims abstract description 16
- 240000008042 Zea mays Species 0.000 claims abstract description 13
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 13
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 11
- 235000005822 corn Nutrition 0.000 claims abstract description 11
- 239000002609 medium Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000186000 Bifidobacterium Species 0.000 claims description 15
- 238000010612 desalination reaction Methods 0.000 claims description 14
- 244000298479 Cichorium intybus Species 0.000 claims description 13
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 241000235649 Kluyveromyces Species 0.000 claims description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 11
- 240000008790 Musa x paradisiaca Species 0.000 claims description 10
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 10
- 238000002525 ultrasonication Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 241000186012 Bifidobacterium breve Species 0.000 claims description 4
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 241000170280 Kluyveromyces sp. Species 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 1
- 241000235342 Saccharomycetes Species 0.000 abstract description 16
- 206010010774 Constipation Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 210000000936 intestine Anatomy 0.000 abstract description 6
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 abstract description 6
- 229960000511 lactulose Drugs 0.000 abstract description 6
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 4
- 229920001542 oligosaccharide Polymers 0.000 abstract description 4
- 230000008855 peristalsis Effects 0.000 abstract description 4
- 206010012735 Diarrhoea Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000474 nursing effect Effects 0.000 abstract description 3
- 230000002457 bidirectional effect Effects 0.000 abstract description 2
- 230000004907 flux Effects 0.000 abstract description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 2
- 230000004913 activation Effects 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000001072 colon Anatomy 0.000 description 10
- 239000002994 raw material Substances 0.000 description 7
- 240000002900 Arthrospira platensis Species 0.000 description 6
- 235000016425 Arthrospira platensis Nutrition 0.000 description 6
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940082787 spirulina Drugs 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920001202 Inulin Polymers 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 239000000976 ink Substances 0.000 description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 oligosaccharides small molecule Chemical class 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 2
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 108010027322 single cell proteins Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000009955 starching Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of for adjusting the preparation of infant's function of intestinal canal, it is to utilize lactic acid bacteria and saccharomycete co-fermentation algae essence, the fermentation of seaweed extracting solution rich in the oligosaccharides such as algal polysaccharides and lactulose and high-content probiotics is obtained, then is mutually configured to resistant starch and corn peel powder.The beneficial effect is that preparation provided by the present invention can promote infant's intestinal peristalsis, there is the loose internal excrement of softening, increase excrement flux, improve constipation, the effect of diarrhea bidirectional modulation；By increasing the proliferation and field planting of intestine beneficial bacteria colony, effectively nursing infant is helped to establish intestine beneficial bacteria colony, it is long to benefit from the time for no dependence；Heat is low, highly-safe, and stability is good.
Description
Technical field
The invention belongs to infant food technical fields, more particularly, to one kind for adjusting infant's function of intestinal canal
Preparation.
Background technique
Constipation is infant's common disease, brings pain and worry to infant and its parent, influences infant's quality of life.
Its disease incidence is high, accounts for comprehensive Pediatric Clinic 5%~10%, and the 25% of Zhan little Er gastrointestinal disease outpatient service.Wherein functional consitipation (FC)
Account for 90% or more of constipation for children.Functional consitipation is primarily referred to as the function of intestinal tube, the function of gastrointestinal tract changes, due to body
Liquid is adjusted or the extremely caused defecation of nerve modulation is unsmooth.
Functional consitipation can be significantly improved by adjusting intestinal flora, most important to infant development and immune system building,
It is also in close relations with adult health and disease.When infantile period (nascent 1000 d) is the key that intestinal flora building colonizes
Phase, the health status for colonizing diversity and affecting the building of infant immunisation system and future growth of this stage intestinal flora.
Intestinal flora plays an important role to the metabolic function of human body, immune function and health status.Intestinal flora participates in
The metabolism of nutriment is conducive to the digestion and absorption of host.Intestinal flora participates in the metabolism of cholesterol, and enteric microorganism can be straight
The cholesterol in metabolism enteron aisle is connect, in addition, intestinal flora also plays important work in the metabolic process of bile acid and BILE PIGMENTS
With intestinal flora mainly passes through hydrolysis amido bond, and release free bile acid is to be metabolized the bile acid in terminal ileum or colon.
The metabolite of intestinal flora can influence body's immunity, this mainly by on immunocyte and enterocyte
G protein coupled receptor reaction influences immune function.
However, so far most of are studies have shown that simple probiotics is temporary to increase intestinal flora
The quantity of middle probiotics, but it is not carried out the mode that probiotics colonizes for a long time in enteron aisle.
Summary of the invention
The present invention is directed to problem above, provides a kind of for adjusting the preparation of infant's function of intestinal canal, and preparation includes
Fermentation of seaweed extract, the fermentation of seaweed extract are prepared by the following method:
S1: taking new fresh seaweed to clean ultrasonication after desalination, and the power of ultrasonication is 300~600 w, and the time is 2~5
Min obtains algae essence；
S2: the preparation of algae essence fermentation medium: take 5 ~ 10g of lactose, 5 ~ 10g of glucose and 200~400 g of algae essence molten
It is dissolved in 1000 mL water, sterilize to obtain algae essence fermentation medium；
S3: it is inoculated in after bacterial strain is activated in 100 mL algae essence fermentation mediums in step S2, at 30~40 DEG C, 200
24~36 h are cultivated under the conditions of r/min, obtain fermentation liquid, wherein bacterial strain is one of lactic acid bacteria or food yeast bacterium or one kind
More than, the bacteria suspension concentration of activated strains is 104~106CFU/ml, every kind of strain inoculated amount are 1~5 ml；
S4: fermentation liquid described in step S3 is collected, and is concentrated, and freeze-drying crushes to obtain fermentation of seaweed extract.
The present invention by fermentation algae essence, by seaweed nutriment (such as: VitAVitE, thiamine,
Riboflavin, pyridoxol, vitamin B12, vitamin C, biotin, inositol, folic acid, calcium pantothenate and niacin) it discharges and accumulates, and
In fermentation process, a large amount of algal polysaccharides, the oligosaccharides small molecule such as lactulose are produced, these oligosaccharides small molecules can promote enterobacteriaceae
The short chain fatty acids that group generates increase excrement water content, and short chain fatty acids can be pierced to promote colonic absorption water and salt
Swash colonic mucosa growth.In addition, polysaccharides compound can be used as immunologic adjuvant enhancement antigen and body's immunity.
Further, further include witloof juice in fermentation of seaweed culture medium in the step S2, grinding, juicing or even can be passed through
The blade for starching witloof obtains juice.
Witloof is medical and edible dual purpose plant, and root contains inulin (synanthrin) and aromatic substance, can promote human digestive organ's activity,
In addition in witloof be rich in amino acid, folic acid, vitamin, carrotene and calcium, iron, copper etc., also containing protein and fat and
Carbohydrate can provide nutriment abundant for the microorganism cultivated.And pass through the fermentation of lactic acid bacteria and saccharomycete,
A large amount of inulin are obtained, it is a kind of water-soluble dietary fiber that inulin, which is a kind of Fructooligosaccharides, and gastric acid can not be digested or molten
Solution, after reaching colon, many beneficial microbes can be using inulin as nutrients in colon.After human body takes in inulin, in enteron aisle
The abundance of Bifidobacterium can be significantly increased, and the fermentation of Bifidobacterium can generate certain lactic acid, and lactic acid can reduce in enteron aisle
PH value, while can also secrete certain antibacterial substance, mycin reduces the probability of enteric infection.
Further, lactose is 10g/L, glucose 5g/L, algae essence in fermentation of seaweed culture medium in the step S2
For 200g/L, witloof juice is 100g/L.
Further, the seaweed is one of microalgae or a variety of.
Contain chlorophyll a in microalgae, and can be carried out photosynthesis, belongs to one kind of protist.Contain in microalgae cell:
The nutrition of the high values such as protein, lipid, polysaccharides, beta carotene, a variety of inorganic elements (such as Cu, Fe, Se, Mn, Zn etc.)
Ingredient and industrial chemicals.The protein content of microalgae is very high, is an important sources of single cell protein (SCP).Microalgae also contains
There is VitAVitE, thiamine, riboflavin, pyridoxol, vitamin B12, vitamin C, biotin, inositol, folic acid, general
Sour calcium and niacin etc..
Further, lactic acid bacteria described in the step S3 is lactobacillus fermenti, and bifidobacterium breve, lactobacillus acidophilus, animal are double
One of discrimination bacillus, bifidobacterium lactis, Lactobacillus rhamnosus are a variety of, and the food yeast bacterium is Kluyveromyces sp.
Further, the Kluyveromyces sp is lactic acid yeast kluyveromyces.
Lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, Lactobacillus rhamnosus are all the safety suitable for infant
Reliable probiotics forms higher viable count by the available accumulation of fermentation thalli, after taking in human body, can increase enteron aisle
The quantity of group's beneficial bacterium, and then help to assimilate, Kluyveromyces sp is can consumption by Lactose conversion at lactulose
Saccharomycete.
Bifidus factor (N- acetyl-β-D- glucosaminide) in lactulose and breast milk in product has similar action, energy
Nursing infant is enough helped to establish enteron aisle bifid flora into that can reach large intestine in vivo and be utilized by intestinal beneficial bacteriums such as Bifidobacteriums, to it
Proliferation plays good effect.In addition, lactulose can also be acidified colonic environment, enteron aisle reduction potential is reduced, inhibits harmful bacteria
Growth.The sugariness of lactulose is higher than lactose, is the 48%~70% of sucrose, and have heat low, and highly-safe, stability is good,
Not the features such as Maillard reaction does not occur, at the same time as functional sweetener.
Further, thickening temperature is≤40 DEG C in the step S4.
Due to containing a large amount of probiotics and bioactive substance in fermentation liquid, the concentration of lower temperature facilitates active
Holding is survived with thallus.
Further, the preparation includes following components: 50 ~ 70 parts of fermentation of seaweed extract, 10 ~ 15 parts of resistant starch, beautiful
10 ~ 20 parts of powder of kind skin of rice.
Oligosaccharide in resistant starch and fermentation of seaweed extract can ferment in colon after entering enteron aisle and generate gas
The short chain fatty acids such as body and acetic acid, propionic acid, butyric acid, butyric acid etc. can reduce gut pH, so that enteron aisle is in acidic environment,
It is more advantageous to the growth of the probiotics such as Bifidobacterium and lactobacillus, inhibits the growth of putrefactivebacteria, and promotes enterocinesia and promotes
Defecation.
Contain a large amount of dietary fibers, active polysaccharide and viscose in corn peel, beneficial bacteria of intestinal tract can be promoted
Activity and field planting, and then adjust function of intestinal canal.And raw materials for production maize peel is in process by degreasing, friction, shearing, molten
The effects of melting, mixing, which makes molecule that fracture and recombination, close fiber crystallite structure occur, becomes loose, and macromolecular structure mutually becomes
Change, molecular weight reduces, and generates branch, and hydrophilic radical increases, and changes its chemical component and physicochemical property, soluble component is substantially
Degree increases, and firm three-dimensional porous network structure can be formed in animal intestines and stomach.The anti-constipation mechanism of maize peel powder may be due to it
The three-dimensional porous network structure of formation, it is stronger to the absorption and holding capacity of moisture, and there is biggish expansive force, retention ability
With combine waterpower, form soft wet class micelle sample substance in stomach and intestine, and these substances not by or seldom disappeared by body
Change and absorb, into after colon, there is stronger facilitation to the wriggling of enteron aisle, shorten excrement by the time of colon, subtract
Lacked colon to the soak time of moisture, improved the water content of excrement, excrement is made to become soft and enlarged volume, stimulation colon with
Rectum is easy to drain, and prevents the formation of stool, plays the role of the anti-constipation of defaecation.
Further, the preparation includes following components: 70 parts of fermentation of seaweed extract, 10 parts of resistant starch, and corn peel
20 parts of powder.
Further, the resistant starch is banana resistant starch.
Resistance starch content reaches 60% in green banana, and banana resistant starch is not digested absorption in small enteral；Reach large intestine
The nutrient source for becoming large intestine microorganism afterwards, can produce short chain fatty acids metabolin, reduce colon pH value, promote intestinal peristalsis.
Compared with the existing technology, the present invention has the advantage that and effect:
Products therefrom of the present invention can promote infant's intestinal peristalsis, have the loose internal excrement of softening, increase excrement flux, just
Secret, diarrhea bidirectional modulation effect；By increasing the proliferation and field planting of intestine beneficial bacteria colony, effectively helping nursing infant to establish enteron aisle has
It is long to benefit from the time without dependence for bacteria group；Heat is low, highly-safe, and stability is good.
Specific embodiment
Further illustrate the present invention below in conjunction with specific embodiment, but embodiment the present invention is not done it is any type of
It limits.Unless stated otherwise, the present invention uses reagent, method and apparatus is the art conventional reagents, method and apparatus.
Unless stated otherwise, agents useful for same and material of the present invention are commercially available.
Bacterial strain is general from China typical culture collection center (CCTCC) (China, Wuhan) and China in following embodiment
Logical Microbiological Culture Collection administrative center (CGMCC) (China, Beijing) is bought.
The preparation of activation medium in following embodiment:
1) lactic acid bacteria activation medium: peptonized milk 15g, yeast extract 5g, potassium dihydrogen phosphate 2g, glucose 10g, tomato leach powder
2.5, Tween 80 mL, adjusting pH is 6.8, is sterilized spare.
2) saccharomycete activation medium: 1% Yeast Extract (yeast extract), 2% Peptone (peptone), 2%
2% agar powder is added in Dextrose (glucose) (glucose), sterilizes spare.
Embodiment 1:
Bacterial strain activation:
By lactobacillus fermenti CECT5716, bifidobacterium breve M-16V, it is inoculated in lactic acid bacteria activation medium, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 600 w, and the time is 2 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 5g, glucose 5g and 400 g of algae essence, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by after activation lactic acid bacteria and yeast strain be inoculated in algae essence fermentation medium, at 40 DEG C, 200 r/
It is cultivated under the conditions of min for 24 hours, obtains fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml, inoculation
Amount is lactic acid bacteria and each 10ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of rotary evaporation concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 70 parts of fermentation of seaweed extract, banana
10 parts of resistant starch, 10 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Embodiment 2:
Bacterial strain activation:
Lactobacillus acidophilus NCFM, animal bifidobacteria Bb-12, bifidobacterium lactis Bi-07 are inoculated in lactic acid bacteria activation culture
Base, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 300 w, and the time is 5 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 10g, glucose 5g and 200 g of algae essence, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by the strain inoculated after activation in algae essence fermentation medium in step S2, at 37 DEG C, 200 r/min items
24 h are cultivated under part, obtain fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml, inoculum concentration are
Lactic acid bacteria and each 10ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 60 parts of fermentation of seaweed extract, banana
10 parts of resistant starch, 20 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Embodiment 3:
Bacterial strain activation:
Bifidobacterium lactis HN019 is inoculated in lactic acid bacteria activation medium, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 400 w, and the time is 5 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 8g, glucose 5g and 400 g of algae essence, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by the strain inoculated after activation in algae essence fermentation medium in step S2, at 37 DEG C, 400 r/min items
24 h are cultivated under part, obtain fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml, inoculum concentration are
Lactic acid bacteria and each 15ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 70 parts of fermentation of seaweed extract, banana
15 parts of resistant starch, 16 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Embodiment 4:
Bacterial strain activation:
Lactobacillus fermenti CECT5716 and bifidobacterium breve M-16V are inoculated in lactic acid bacteria activation medium, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 500 w, and the time is 5 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 6g, glucose 8g and 300 g of algae essence, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by the strain inoculated after activation in 100 mL algae essence fermentation mediums in step S2, at 37 DEG C, 220 r/
36 h are cultivated under the conditions of min, obtain fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml connects
Kind amount is lactic acid bacteria and each 10ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 60 parts of fermentation of seaweed extract, banana
12 parts of resistant starch, 20 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Embodiment 5:
Bacterial strain activation:
Lactobacillus rhamnosus HN001 is inoculated in lactic acid bacteria activation medium, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 500 w, and the time is 4 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 10g, glucose 5g and algae essence 200g, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by the strain inoculated after activation in algae essence fermentation medium in step S2, at 37 DEG C, 220 r/min items
24 h are cultivated under part, obtain fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml, inoculum concentration are
Lactic acid bacteria and each 10ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 70 parts of fermentation of seaweed extract, banana
15 parts of resistant starch, 20 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Embodiment 6:
Bacterial strain activation:
Lactobacillus acidophilus NCFM, bifidobacterium lactis HN019 are inoculated in lactic acid bacteria activation medium, 37 DEG C of cultures are for 24 hours.
Lactic acid yeast kluyveromyces are inoculated in saccharomycete activation medium, 37 DEG C of cultures are for 24 hours.
The preparation of fermentation of seaweed extract:
S1: taking new fresh seaweed (chlorella, spirulina) to clean removal of impurities, and clear water impregnates 6h desalination, and the seaweed after taking desalination is surpassed
Sound broken wall, the power of ultrasonication are 500 w, and the time is 5 min, obtain algae essence；
S2: the preparation of algae essence fermentation medium: taking lactose 8g, glucose 8g and 330 g of algae essence, and witloof juice is
100g is dissolved in 1000 mL water and dissolving, and sterilize to obtain algae essence fermentation medium；
S3: by the strain inoculated after activation in algae essence fermentation medium in step S2, at 37 DEG C, 400 r/min items
24 h are cultivated under part, obtain fermentation liquid, wherein bacteria suspension (or spore liquid) concentration of activated strains is 106 CFU/ml, inoculum concentration are
Lactic acid bacteria and each 15ml of saccharomycete；
S4: fermentation liquid described in step S3 is collected, and 40 DEG C of concentrations, freeze-drying crushes to obtain fermentation of seaweed extract.
It is a kind of for adjusting the preparation of infant's function of intestinal canal, including following components: 70 parts of fermentation of seaweed extract, banana
10 parts of resistant starch, 20 parts of corn peel powder, the above raw material is uniformly mixed.Condition of storage: 20 DEG C hereinafter, shady and cool dry
Place, closed preservation.
Experimental example 1
Fermentation of seaweed extract is to Bifidobacterium proliferation function
It is the extraction of 1,2,3(fermentation of seaweed of test group that fermentation of seaweed extract in embodiment 1 is added in Bifidobacterium basic culture solution
Object content is respectively set to 10mg/mL, 20mg/mL, 30mg/mL), basic culture solution is control group, and each culture solution is respectively charged into
In test tube, 10 mL/ branch loading amounts, inoculation bifidobacterium lactis strain (bacterial strain HN019) 1 mL(is initial after 121 DEG C of 15 min of sterilizing
Bacteria concentration is 102, 37 DEG C of Anaerobic culturel 1h ~ 4h.
Wherein, basic culture solution are as follows: peptonized milk 15g, yeast extract 5g, potassium dihydrogen phosphate 2g, glucose 10g, tomato leaching
Powder 2.5 out, Tween 80 mL, adjusting pH is 6.8, is sterilized spare.
1 mL Spawn incubation sample liquid is taken to measure bifidobacterium cells quantity respectively.With bifidobacterium cells in basic culture solution
Quantity is reference, measures each concentration fermentation of seaweed extract to the proliferation function of Bifidobacterium.
Table 1: proliferation function of the fermentation of seaweed extract to Bifidobacterium
As the result is shown: addition fermentation of seaweed extract can promote the rapid growth of Bifidobacterium, and with fermentation of seaweed extract
The increase of content, the increased speed of Bifidobacterium thallus significantly increase.
Experimental example 2
Adjust function of intestinal canal measurement
The preparation that gained in embodiment 3 is adjusted to infant's function of intestinal canal, is deployed, preparation additive amount is respectively 100mg/ with water
ML, 500mg/mL, 1g/mL are as experimental group low dose group, middle dose group and high dose group.
Constipation Model preparation: after being deprived of food but not water for 24 hours, in addition to blank group, remaining each group is with 50mg/kg dosage compound
Fragrant promise ester suspension oral gavage.Appearance, fecal grains and the character of mouse are observed after administration.Constipation Model replicates Success Flag: with
Occur that appearance is shrivelled, modest, weight loss, urine jaundice dry and hard excrement occurs, excrement particles are tiny；Abdominal cavity inner body is shown in dissection
Liquid is reduced, and excrement block concentrates at colon, spherical in shape or beading, and jejunum, ileum are remained without obvious excrement.
Successful 48 mouse of modeling are randomly divided into 4 groups: it is low, in, high dose group is taken preparation 1 time daily, is continuously given
Give 7 d.Remaining 12 mouse the water of amount of formulation such as only take as blank control group every time.Last is given 1 after preparation or water
H gives 1% prepared Chinese ink aqueous solution of mouse gavaging, 1. 0 mLg- 1, and cervical dislocation puts to death animal to 25min immediately after gavaging prepared Chinese ink, opens
Abdominal cavity separates mesenterium, and small intestine is pulled into straight line, measure Length of intestine by clip upper end from the intestinal tube of pylorus, lower end to ileocecus
For " total small intestinal length ", it is from pylorus to prepared Chinese ink forward position " prepared Chinese ink propulsion length ", calculates ink progradation.
Table 2: for adjusting propulsion rate of the preparation to excrement of infant's function of intestinal canal
Gained of the invention adjusts the preparation of infant's function of intestinal canal, the influence to normal mouse gastrointestinal propulsive effect function and bowel movement function
It is low, in, high dose formulations all have apparent facilitation to the gastrointestinal peristalsis function of normal mouse, compared with blank control group,
Middle dose group propulsion rate improves 17.56%；High dose group improves 20.59 %.The middle and high dosage group of mouse feces volume (g) is obvious in 7d
More than blank control group and low dose group.
Originally the experimental results showed that, invention formulation can obviously increase the defecation frequency of normal mouse, small to constipation type constipation
Mouse has effects that relief of constipation, and high dose group effect is best, and the anti-constipation effect of explanation has certain dose-effect relationship, to just
Normal gastrointestinal motility in mice function has apparent facilitation, hence it is evident that increases normal and constipation type mice with constipation defecation frequency, contracting
The defecation time of short and small mouse has apparent anti-constipation effect.
Experimental example 3
Studies on acute toxicity
Mouse 20 of health, are randomly divided into 2 groups, every group 10, half male and half female is standard according to the body of mouse using 10 g/kg
The stomach-filling preparation for oral administration for adjusting infant's function of intestinal canal is weighed, 14 d are observed continuously.Observed content include: dead mouse number and
The respective death time；Mouse weight；Whether poisoning and its reaction symptom, observation skin, coat, eyes and the case where mucous membrane are exhaled
Suction, circulation, central nervous system of advocating peace certainly and four limbs activity and the variation of behavior etc. are paid special attention to have atremia, be shied
Faint, diarrhea, it is drowsiness phenomena such as；
When 10000 mg/kg of preparation of mouse adjusting infant's function of intestinal canal for oral administration, within the observation period, drinking-water and feeding are just
Often, body weight increase each group is consistent, does not occur being poisoned and dead.By toxicological evaluation standard, it may not be necessary to measure median lethal dose.Root
It is classified according to xenobiotics acute toxicity, adjusting infant's function of intestinal canal is nontoxic or toxicity is minimum.
Under the premise of without departing substantially from the spirit and scope of the present invention (being more specifically set forth in appended claims), ability
Domain those of ordinary skill can be to present invention implementation these or other modifications and changes.It is further understood that the side of different embodiments
Face can exchange in whole or in part.Moreover, it will be appreciated by the skilled addressee that the description of front is exemplary only and nothing
Meaning is limited in the invention further described in these appended claims in this way.Therefore, spirit and scope of the appended claims
It should not be limited by description form wherein included.
Claims (10)
1. a kind of for adjusting the preparation of infant's function of intestinal canal, which is characterized in that its preparation includes fermentation of seaweed extract, institute
Fermentation of seaweed extract is stated to be prepared by the following method:
S1: taking new fresh seaweed to clean ultrasonication after desalination, and the power of ultrasonication is 300~600 w, and the time is 2~5
Min obtains algae essence；
S2: the preparation of algae essence fermentation medium: take 5 ~ 10g of lactose, 5 ~ 10g of glucose and 200~400 g of algae essence molten
It is dissolved in 1000 mL water, sterilize to obtain algae essence fermentation medium；
S3: being inoculated in 100 mL algae essence fermentation mediums in step S2 after bacterial strain is activated, at 30~40 DEG C, 200 ~
Under the conditions of 400 r/min cultivate 24~36 h, obtain fermentation liquid, wherein bacterial strain be one of lactic acid bacteria or food yeast bacterium or
More than one, the bacteria suspension concentration of activated strains is 104~106 CFU/ml, every kind of strain inoculated amount are 1~5 ml；
S4: fermentation liquid described in step S3 is collected, and is concentrated, and freeze-drying crushes to obtain fermentation of seaweed extract.
2. according to the preparation for being used to adjust infant's function of intestinal canal described in claim 1, which is characterized in that seaweed in the step S2
It further include witloof juice in fermentation medium.
3. according to claim 1 or claim 2 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that the step S2
Lactose is 10g/L, glucose 5g/L, algae essence 200g/L in middle fermentation of seaweed culture medium, and witloof juice is 100g/L.
4. according to claim 1 ~ 3 for adjusting the preparation of infant's function of intestinal canal described in any one, which is characterized in that described
Seaweed is one of microalgae or a variety of.
5. according to claim 1 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that described in the step S3
Lactic acid bacteria is lactobacillus fermenti, bifidobacterium breve, lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, Lactobacillus rhamnosus
One of or it is a variety of, the food yeast bacterium be Kluyveromyces sp.
6. according to claim 5 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that the kluyveromyces
Bacterium is lactic acid yeast kluyveromyces.
7. according to claim 1 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that dense in the step S4
Contracting temperature is≤40 DEG C.
8. according to claim 1 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that according to parts by weight,
The preparation includes following components: 50 ~ 70 parts of fermentation of seaweed extract, 10 ~ 15 parts of resistant starch, 10 ~ 20 parts of corn peel powder.
9. according to claim 8 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that the preparation include with
Lower component: 70 parts of fermentation of seaweed extract, 10 parts of resistant starch, 20 parts of corn peel powder.
10. according to claim 8 or claim 9 for adjusting the preparation of infant's function of intestinal canal, which is characterized in that the resistance is formed sediment
Powder is banana resistant starch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910502600.0A CN110150651A (en) | 2019-06-11 | 2019-06-11 | It is a kind of for adjusting the preparation of infant's function of intestinal canal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910502600.0A CN110150651A (en) | 2019-06-11 | 2019-06-11 | It is a kind of for adjusting the preparation of infant's function of intestinal canal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110150651A true CN110150651A (en) | 2019-08-23 |
Family
ID=67628521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910502600.0A Pending CN110150651A (en) | 2019-06-11 | 2019-06-11 | It is a kind of for adjusting the preparation of infant's function of intestinal canal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110150651A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110172106A (en) * | 2019-06-11 | 2019-08-27 | 深圳保时健生物工程有限公司 | A kind of peach gum polysaccharide iron and its application |
| NL2025592B1 (en) * | 2020-05-15 | 2021-11-30 | Ful Foods B V | Drink composition comprising microalgae |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101427790A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk with additive oligose suitable for baby of 12 to 36 months old |
| CN108902595A (en) * | 2018-06-20 | 2018-11-30 | 福建农林大学 | A kind of preparation method of the fermentation of seaweed beverage rich in viable lactic acid bacteria |
-
2019
- 2019-06-11 CN CN201910502600.0A patent/CN110150651A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101427790A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk with additive oligose suitable for baby of 12 to 36 months old |
| CN108902595A (en) * | 2018-06-20 | 2018-11-30 | 福建农林大学 | A kind of preparation method of the fermentation of seaweed beverage rich in viable lactic acid bacteria |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110172106A (en) * | 2019-06-11 | 2019-08-27 | 深圳保时健生物工程有限公司 | A kind of peach gum polysaccharide iron and its application |
| NL2025592B1 (en) * | 2020-05-15 | 2021-11-30 | Ful Foods B V | Drink composition comprising microalgae |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beumer et al. | Campylobacter jejuni non-culturable coccoid cells | |
| CN103230005B (en) | The method for the treatment of and/or preventing infections in infants delivered via caesarean section | |
| CN108004189A (en) | A kind of compound probiotic lactic acid bacteria powder and preparation method and application | |
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN102304489B (en) | Lactobacillus reuteri strain and application thereof | |
| CN110101722A (en) | A kind of compound probiotic microbial inoculum is used to prepare the purposes for the treatment of ulcerative colitis product | |
| CN102212495B (en) | Lactobacillus acidophilus and application thereof | |
| CN100484964C (en) | New use of tremella heteropolysaccharide or its extract | |
| CN104542977B (en) | A kind of health beverages and preparation method containing yam extract and bifidobacterium bifidum | |
| CN101260377B (en) | Animal bifidobacteria and use thereof | |
| CN108783462A (en) | A kind of industrial process of beneficial bacteria of intestinal tract preparation | |
| AU3995699A (en) | A beneficial microbe composition, new protective materials for the microbes, the method to prepare and uses thereof | |
| CN103333847B (en) | Lactobacillus fermenti grx08 with function of assisting blood fat reduction and application of lactobacillus fermenti grx08 | |
| CN104642870A (en) | Prebiotics composition | |
| CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
| WO2008023580A1 (en) | Animal feed additive | |
| CN1273838A (en) | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics | |
| CN106350468A (en) | Novel lactobacillus acidophilus | |
| CN108770974A (en) | A kind of antianaphylactic probiotic gel candy and preparation method thereof | |
| CN103445048A (en) | Soybean oligosaccharide product containing probiotics and preparation method thereof | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN104430847A (en) | Lactobacillus fermentum Lee working leavening agent product and constipation-prevention and health application thereof | |
| CN110150651A (en) | It is a kind of for adjusting the preparation of infant's function of intestinal canal | |
| CN104431352B (en) | A kind of preparation method and application of growth promotion symphysis unit bacterium solution | |
| JP5610472B2 (en) | Novel lactic acid bacteria and novel lactic acid bacteria-containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190823 |
|
| RJ01 | Rejection of invention patent application after publication |